Emerging personalized approaches for the management of advanced urothelial carcinoma

Expert Review of Anticancer Therapy

Volumn 12, Issue 12, 2012, Pages 1537-1543

  Tsao, Che Kai ^a   Gartrell, Benjamin A ^a   Oh, William K ^a   Galsky, Matthew D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; bladder cancer; chemotherapy; neoadjuvant therapy; personalized medicine; urothelial carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOVITINIB; DOXORUBICIN; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEMCITABINE; LAPATINIB; METHOTREXATE; PACLITAXEL; PROTEIN P53; TRASTUZUMAB; VINBLASTINE;

ADVANCED CANCER; BLADDER CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PROGNOSIS; CDKN2A GENE; CYSTECTOMY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; FGFR3 GENE; GENE; GENE EXPRESSION; GENOMICS; HUMAN; LYMPH NODE DISSECTION; METASTATIC BLADDER CANCER; METASTATIC UROTHELIAL CARCINOMA; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; OVARY CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PELVIS LYMPH NODE; PERSONALIZED MEDICINE; PIK3CA GENE; RB1 GENE; RECURRENCE RISK; REVIEW; SOMATIC MUTATION; STOMACH CANCER; TP53 GENE; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; CYSTOSCOPY; HUMANS; INDIVIDUALIZED MEDICINE; URINARY BLADDER NEOPLASMS;

EID: 84871501689     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.141     Document Type: Review

References (46)

1. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. J. Clin. Oncol. 24(35), 5552-5564 (2006
2. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 5(11), e13821 (2010
3. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23(6), 675-680 (2009
4. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001
5. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859-866 (2003
6. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J. Clin. Oncol. 29(16), 2171-2177 (2011
7. Bochner BH, Kattan MW, Vora KC; International Bladder Cancer Nomogram Consortium. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J. Clin. Oncol. 24(24), 3967-3972 (2006
8. Als AB, Dyrskjøt L, von der Maase H et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced ladder cancer. Clin. Cancer Res. 13
9. Pt 1), 4407-4414 (2007
10. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24(5), 778-789 (2006
11. Mitra AP, Pagliarulo V, Yang D et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J. Clin. Oncol. 27(24), 3929-3937 (2009
12. Karam JA, Lotan Y, Karakiewicz PI et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 8(2), 128-136 (2007
13. Shariat SF, Tokunaga H, Zhou J et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 22(6), 1014-1024 (2004
14. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331(19), 1259-1264 (1994
15. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 385(6612), 123-125 (1997
16. Stadler WM, Lerner SP, Groshen S et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 tatus. J. Clin. Oncol. 29(25), 3443-3449 (2011
17. Sternberg CN, Yagoda A, Scher HI et al Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin for transitional cell carcinoma of the urothelium. J. Urol. 133(3), 403-407 (1985
18. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068-3077 (2000
19. Bellmunt J, Von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. Proc. Am. Soc. Clin. Oncol. 25, Abstract 5030 (2007
20. Chow NH, Liu HS, Yang HB, Chan SH, Su IJ. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows Arch. 430(6), 461-466 (1997
21. Mellon JK, Cook S, Chambers P, Neal DE. Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor. Br. J. Cancer 73(5), 654-658 (1996
22. Black PC, Dinney CP. Bladder cancer angiogenesis and metastasis- translation from murine model to clinical trial. Cancer Metastasis Rev. 26(3-4), 623-634 (2007
23. Wülfing C, Machiels JP, Richel DJ et al. A single-arm, multicenter, open-label Phase 2 study of lapatinib as the second-line treatment of patients with locally advanced r metastatic transitional cell carcinoma. Cancer 115(13), 2881-2890 (2009
24. Galsky MD, Zaks T, Hassani H et al. Target-specific randomized discontinuation trial design: A novel approach in molecular therapeutics. Invest. New Drugs 28(2), 194-198 (2010
25. Galsky MD, Von Hoff DD, Neubauer M et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Proceedings of: ASCO Annual Meeting. Orlando, FL, USA, 2009
26. Milowsky GLC, Shi MM, Urbanowitz G, Zhang Y, Sternberg CN. A multicenter, open-label Phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3. Proceedings of: ASCO Annual Meeting. Chicago, IL, USA, 2011
27. Murray D, Britten RA, Liu D, Tessier A, Hutchison MJ. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int. J. Cancer 89, 453-457 (2000
28. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 94(2), 703-708 (1994
29. Rosell R, Lord RVN, Brabender J et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell ung cancer. Clin. Cancer Res. 8, 2286-2291 (2002
30. Gorlick R, Metzger R, Danenberg KD et al. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J. Clin. Oncol. 16(4), 1465-1469 (1998
31. Lenz HJ, Shirota Y, Stoehlmacher J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19, 4298-4304 (2001
32. Soria JC, Olaussen KA, Dunant A et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983-991 (2006
33. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 356(8), 800-808 (2007
34. Reynolds C, Obasaju C, Schell MJ et al. Randomized Phase III trial of gemcitabinebased chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J. Clin. Oncol. 27(34), 5808-5815 (2009
35. Bellmunt J, Paz-Ares L, Cuello M et al.; Spanish Oncology Genitourinary Group. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based hemotherapy. Ann. Oncol. 18(3), 522-528 (2007
36. Dimou A, Agarwal S, Anagnostou V et al. Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am. J. Pathol. 179(2), 580-589 (2011
37. Takata R, Katagiri T, Kanehira M et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 98(1), 113-117 (2007
38. Takata R, Katagiri T, Kanehira M et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res. 11(7), 2625-2636 (2005
39. Williams PD, Cheon S, Havaleshko DM et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res. 69(21), 8302-8309 (2009
40. Maemondo M, Inoue A, Kobayashi K et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-smallcell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010
41. Rosell R, Moran T, Queralt C et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009
42. Sjödahl G, Lauss M, Gudjonsson S et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS ONE 6(4), e18583 (2011
43. Iyer G, Hanrahan AJ, Milowsky MI et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338(6104), 221 (2012
44. Shah JB, McConkey DJ, Dinney CP. New strategies in muscle-invasive bladder cancer: On the road to personalized medicine. Clin. Cancer Res. 17(9), 2608-2612 (2011
45. Pruthi RS, Nielsen M, Heathcote S et al. A Phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Clinical and pathological results. BJU Int. 106(3), 349-354 (2010
46. Levitt JM, Yamashita H, Jian W, Lerner SP, Sonpavde G. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol. Cancer Ther. 9(5), 1128-1135 (2010)